nach oben

Journal of Clinical Immunology

Erschienen in:

01.11.2008

Multiple Sclerosis and Regulatory T Cells

verfasst von: Cristina Maria Costantino, Clare Baecher-Allan, David A. Hafler

Erschienen in: Journal of Clinical Immunology | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Multiple sclerosis (MS) is a complex genetic disease characterized by chronic inflammation of the central nervous system (CNS). The pathology of MS is largely attributed to autoreactive effector T cells that penetrate the blood–brain barrier and become activated within the CNS. As autoreactive T cells are present in the blood of both patients with MS and healthy individuals, other regulatory mechanisms exist to prevent autoreactive T cells from causing immune disorders. Active suppression by regulatory T (Treg) cells plays a key role in the control of self-antigen-reactive T cells and the induction of peripheral tolerance in vivo. In particular, the importance of antigen-specific Treg cells in conferring genetic resistance to organ-specific autoimmunity and in limiting autoimmune tissue damage has been documented in many disease models including MS.

Results

We have found that the frequency of Tregs in MS patients is unchanged from controls, but their function measured in vitro may be diminished, correlating with impaired inhibitory activity in vivo. This review discusses the immunopathology of MS with particular focus given to regulatory T cells and their potential for the development of new therapies to treat this disease.

Mackay RP, Myrianth NC. Multiple sclerosis in twins and their relatives—final report. Arch Neurol 1966;15(5):449–57.PubMed

International Multiple Sclerosis Genetic ConsortiumHafler DA, Compston A, Sawcer S, Lander S, Daly MJ, DeJager PL, de Bakker PIW, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL. Novel risk alleles for multiple sclerosis identified by a whole genome association study. N Engl J Med 2007;357:851–62.PubMedCrossRef

McCarthy MI. Susceptibility gene discovery for common metabolic and endocrine traits. J Mol Endocrin 2002;28:1–17.CrossRef

Kabat EA, Glusman M, Knaub V. Quantitative estimation of the albumin and gamma-globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am J Med 1948;4(5):653–62.PubMedCrossRef

Rivers TM, Sprunt DH, Berry GP. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 1933;58(1):39–U58.CrossRef

Goverman J, et al. Transgenic mice that express a myelin basic protein-specific T-cell receptor develop spontaneous autoimmunity. Cell 1993;72(4):551–60.PubMedCrossRef

Miller DH, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. New Eng J Med 2003;348:15–23.PubMedCrossRef

Ota K, et al. T-cell recognition of an immunodominant myelin basic-protein epitope in multiple-sclerosis. Nature 1990;346(6280):183–7.PubMedCrossRef

Pette M, et al. Myelin basic protein-specific lymphocyte—T lines from MS patients and healthy-individuals. Neurology 1990;40(11):1770–6.PubMed

10.

Martin R, et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T-cell lines from multiple-sclerosis patients and healthy-individuals. J Immunol 1990;145(2):540–8.PubMed

11.

Hahn M, Nicholson MJ, Pyrdol J, Wucherpfennig KW. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat Immunol 2005;6(5):490–6.PubMedCrossRef

12.

Ausubel LJ, et al. Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones. Proc Natl Acad Sci U S A 1996;93(26):15317–22.PubMedCrossRef

13.

Zhang X, et al. Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: implications for the initiation of the autoimmune response in multiple sclerosis. Euro J Immunol 2008;38(5):1297–309.CrossRef

14.

Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985;230(4729):1043–5.PubMedCrossRef

15.

Wucherpfennig KW, Strominger JL. Molecular mimicry in T-cell-mediated autoimmunity—viral peptides activate human T-cell clones specific for myelin basic-protein. Cell 1995;80(5):695–705.PubMedCrossRef

16.

Hemmer B, et al. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J Exp Med 1997;185(9):1651–9.PubMedCrossRef

17.

Lang HL, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002;3(10):940–3.PubMedCrossRef

18.

Lenz DC, et al. A Chlamydia pneumoniae-specific peptide induces experimental autoimmune encephalomyelitis in rats. J Immunol 2001;167(3):1803–8.PubMed

19.

Fujinami RS, et al. Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U S A 1983;80(8):2346–50.PubMedCrossRef

20.

Croxford JL, Anger HA, Miller SD. Viral delifery of an epitope from Haemophilus influenzae induces central nervous system autoimmune disease by molecular mimicry. J Immunol 2005;174(2):907–17.PubMed

21.

Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neuro 2007;61(4):288–99.CrossRef

22.

de Jager PL, et al. Integrating risk factors: HLA-DRB1*1501 and Epstein–Barr virus in multiple sclerosis. Neurology 2008;70(13 part 2):1113–8.PubMed

23.

Lehmann PV, et al. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358(6382):155–7.PubMedCrossRef

24.

Ellmerich S, et al. Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. Eur J Immunol 2004;34(7):1839–48.PubMedCrossRef

25.

Trapp BD, et al. Axonal transection in the lesions of multiple sclerosis. New Eng J Med 1998;338(5):278–85.PubMedCrossRef

26.

Lucchinetti CF, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996;6(3):259–74.PubMedCrossRef

27.

Wucherpfennig KW, et al. T-cell receptor V-alpha-V-beta repertoire and cytokine gene-expression in active multiple-sclerosis lesions. J Exp Med 1992;175(4):993–1002.PubMedCrossRef

28.

Traugott U, Reinherz EL, Raine CS. Multiple-sclerosis—distribution of T-cell subsets within active chronic lesions. Science 1983;219(4582):308–10.PubMedCrossRef

29.

Hauser SL, et al. Immunohistochemical analysis of the cellular infiltrate in multiple-sclerosis lesions. Ann Neurol 1986;19(6):578–87.PubMedCrossRef

30.

Wucherpfennig KW, et al. Gamma-delta T-cell receptor repertoire in acute multiple-sclerosis lesions. Proc Natl Acad Sci U S A 1992;89(10):4588–92.PubMedCrossRef

31.

Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma-cells in perivascular compartment in chronic multiple-sclerosis. Lab Invest 1978;38(4):409–21.PubMed

32.

Prineas J. Pathology of early lesion in multiple-sclerosis. Human Pathol 1975;6(5):531–54.CrossRef

33.

Becher B, et al. Soluble tumor necrosis factor receptor inhibits interleukin 12 production by stimulated human adult microglial cells in vitro. J Clin Invest 1996;98(7):1539–43.PubMedCrossRef

34.

Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, Bruce JN, Kane LP, Kuchroo VK, Hafler DA. TIM-3 is expressed by cells of the innate immune system and promotes tissue inflammation. Science 2007;318(5853):1141–3.PubMedCrossRef

35.

Lehnardt S, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 2003;100(14):8514–9.PubMedCrossRef

36.

Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003;302(5651):1760–5.PubMedCrossRef

37.

Ekdahl CT, et al. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A 2003;100(23):13632–7.PubMedCrossRef

38.

Baranzini SE, et al. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol 2000;165(11):6576–82.PubMed

39.

Mycko MP, et al. Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis. Clin Neurol Neurosurg 2004;106(3):223–9.PubMedCrossRef

40.

Aloisi F, et al. IL-12 production by central nervous system microglia is inhibited by astrocytes. J Immunol 1997;159(4):1604–12.PubMed

41.

Ledeboer A, et al. Interleukin-10, interleukin-4, and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia 2000;30(2):134–42.PubMedCrossRef

42.

Onuki I, et al. Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice. Microsc Res Tech 2001;52(6):731–9.PubMedCrossRef

43.

Ayers MM, et al. Early glial responses in murine models of multiple sclerosis. Neurochem Int 2004;45(2–3):409–19.PubMedCrossRef

44.

Trajkovic V, et al. Astrocyte-induced regulatory T cells mitigate CNS autoimmunity. Glia 2004;47(2):168–79.PubMedCrossRef

45.

Roncarolo MG, et al. Type 1 T regulatory cells. Imm Rev 2001;182:68–79.CrossRef

46.

Pullen AM, Marrack P, Kappler JW. Evidence that MLS-2 antigens which delete V-beta-3+ T-cells are controlled by multiple genes. J Immunol 1989;142(9):3033–7.PubMed

47.

Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101(5):455–8.PubMedCrossRef

48.

Shevach EM, et al. Control of T-cell activation by CD4(+) CD25(+) suppressor T cells. Immunol Rev 2001;182:58–67.PubMedCrossRef

49.

Sakaguchi S, et al. Organ-specific autoimmune-diseases induced in mice by elimination of T-cell subset 1. Evidence for the active participation of T-cells in natural self-tolerance—deficit of a T-cell subset as a possible cause of autoimmune-disease. J Exp Med 1985;161(1):72–87.PubMedCrossRef

50.

Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192(2):295–302.PubMedCrossRef

51.

Baecher-Allan C, et al. CD4+CD25(high) regulatory cells in human peripheral blood. J Immunol 2001;167(3):1245–53.PubMed

52.

Dieckmann D, et al. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001;193(11):1303–10.PubMedCrossRef

53.

Wang J, et al. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007;37:129–38.PubMedCrossRef

54.

Fontenot JD, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22:329–41.PubMedCrossRef

55.

Liu W, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006;203:1701–11.PubMedCrossRef

56.

Seddiki N, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693–700.PubMedCrossRef

57.

Ruprecht CR, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in invlamed synovia. J Exp Med 2005;201:1793–803.PubMedCrossRef

58.

Baecher-Allan CM, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006;176:4622–31.PubMed

59.

Baecher-Allan CM, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Imm Rev 2006;212:203–16.CrossRef

60.

Dieckmann D, et al. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing contact-independent type 1-like regulatory T cells. J Exp Med 2002;196:247–53.PubMedCrossRef

61.

Jonuleit H, et al. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) helper cells. J Exp Med 2002;196:255–60.PubMedCrossRef

62.

Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J Immunol 2002;169(11):6210–7.PubMed

63.

Reijonen H, et al. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 2002;51(5):1375–82.PubMedCrossRef

64.

Viglietta V, et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199(7):971–9.PubMedCrossRef

65.

Huan J, et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005;81(1):45–52.PubMedCrossRef

66.

Venken K, et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006;83(8):1432–46.PubMedCrossRef

67.

Astier AL, et al. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest 2006;116(12):3252–7.PubMedCrossRef

68.

Cao D, et al. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. J Immunol 1998;160:1532–8.

69.

Sugiyama H, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005;174:164–73.PubMed

70.

Lindley S, et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005;54:92–9.PubMedCrossRef

71.

Balandina A, et al. Analysis of CD4+CD25+ cell population in the thymus from myasthenia gravis patients. Ann NY Acad Sci 2003;998:275–7.PubMedCrossRef

72.

Gambineri E, et al. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheum 2003;15:430–5.CrossRef

73.

Hafler DA, et al. Risk alleles for multiple sclerosis identified by a genomewide study. New Eng J Med 2007;357:851–62.PubMedCrossRef

74.

The Wellcome Trust Cast Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661–78.CrossRef

75.

Kohm AP, et al. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002;169(9):4712–6.PubMed

76.

McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 2005;175(5):3025–32.PubMed

77.

Gartner D, et al. CD25 regulatory T cells determine secondary but not primary remission in EAE: impact on long-term disease progression. J Neuroimmunol 2006;172(1–2):73–84.PubMedCrossRef

78.

Zhang X, et al. Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells. Int Immunol 2006;18(4):495–503.PubMedCrossRef

79.

Korn T, et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007;13(4):423–31.PubMedCrossRef

Titel: Multiple Sclerosis and Regulatory T Cells
verfasst von: Cristina Maria Costantino
Clare Baecher-Allan
David A. Hafler
Publikationsdatum: 01.11.2008
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 6/2008
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-008-9236-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Results

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2008

Role of TGF-β in the Induction of Foxp3 Expression and T Regulatory Cell Function

TGF-β and Regulatory T Cell in Immunity and Autoimmunity

Limited T-Cell Receptor Diversity Predisposes to Th2 Immunopathology: Involvement of Tregs and Conventional CD4 T Cells

Peripherally Induced Treg: Mode, Stability, and Role in Specific Tolerance

The IL-2/CD25 Pathway Determines Susceptibility to T1D in Humans and NOD Mice